NASDAQ:DCGO DocGo (DCGO) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free DCGO Stock Alerts $3.62 +0.01 (+0.28%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$3.55▼$3.7050-Day Range$3.25▼$4.1352-Week Range$2.78▼$10.82Volume766,670 shsAverage Volume1.48 million shsMarket Capitalization$377.10 millionP/E Ratio51.71Dividend YieldN/APrice Target$10.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DocGo alerts: Email Address DocGo MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside199.3% Upside$10.83 Price TargetShort InterestHealthy10.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$36,100 Bought Last QuarterProj. Earnings Growth25.71%From $0.35 to $0.44 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector52nd out of 918 stocksHealth Services Industry1st out of 10 stocks 4.5 Analyst's Opinion Consensus RatingDocGo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDocGo has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.71% of the float of DocGo has been sold short.Short Interest Ratio / Days to CoverDocGo has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in DocGo has recently decreased by 11.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDocGo does not currently pay a dividend.Dividend GrowthDocGo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCGO. Previous Next 1.9 News and Social Media Coverage News SentimentDocGo has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for DocGo this week, compared to 4 articles on an average week.MarketBeat Follows9 people have added DocGo to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DocGo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $36,100.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.78% of the stock of DocGo is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of DocGo is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for DocGo are expected to grow by 25.71% in the coming year, from $0.35 to $0.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DocGo is 51.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.46.Price to Earnings Ratio vs. SectorThe P/E ratio of DocGo is 51.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 185.59.Price to Earnings Growth RatioDocGo has a PEG Ratio of 0.36. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioDocGo has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About DocGo Stock (NASDAQ:DCGO)DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Read More DCGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCGO Stock News HeadlinesApril 22, 2024 | businesswire.comDocGo to Announce First Quarter 2024 Results on Wednesday, May 8, 2024April 22, 2024 | americanbankingnews.comDocGo Inc. (NASDAQ:DCGO) Receives $10.83 Consensus PT from AnalystsApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 19, 2024 | americanbankingnews.comTraders Buy High Volume of Put Options on DocGo (NASDAQ:DCGO)April 17, 2024 | msn.comDocGo (DCGO) Price Target Decreased by 7.98% to 10.08April 12, 2024 | investing.comStifel cuts DocGo stock target, maintains buy amid contract shiftApril 11, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring DocGo Through Analyst InsightsApril 10, 2024 | businesswire.comDocGo Signs Extension and Begins Planned Transition of Asylum Seeker Contract with New York City HPDApril 29, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 10, 2024 | msn.comDocGo slips as New York City moves to end migrant contractApril 2, 2024 | businesswire.comDocGo Becomes Official Partner of New York City Football ClubMarch 29, 2024 | businesswire.comDOCGO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DocGo Inc. - DCGOMarch 28, 2024 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About DocGo Inc. (NASDAQ:DCGO)?March 20, 2024 | markets.businessinsider.comDocGo Inc. (DCGO) Investor Alert: Grabar Law Office Investigates Claims on Behalf Of DocGo InvestorsMarch 20, 2024 | investing.comDocGo CFO Norman Rosenberg buys $36.1k in company sharesMarch 20, 2024 | seekingalpha.comDocGo: Upside Remains Attractive After Share Price DeclineMarch 20, 2024 | businesswire.comDocGo Leadership Purchase Shares in Open MarketMarch 14, 2024 | nz.finance.yahoo.comTyler Perry’s Sistas Sets Season 7 Return Date Ahead of Midseason Finale — Watch Exclusive TrailerMarch 14, 2024 | businesswire.comDocGo Announces Repurchases of Common Stock and Adoption of 10b5-1 Trading Plan for Share Repurchase ProgramMarch 1, 2024 | finance.yahoo.comDocGo Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | markets.businessinsider.comExpert Outlook: DocGo Through The Eyes Of 4 AnalystsFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for DocGo: Strong FY23 Finish and Promising FY24 Outlook Fuel Growth ProspectsFebruary 29, 2024 | insidermonkey.comDocGo Inc. (NASDAQ:DCGO) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | benzinga.comRecap: DocGo Q4 EarningsFebruary 28, 2024 | msn.comDocGo GAAP EPS of $0.06, revenue of $199.2MFebruary 28, 2024 | finance.yahoo.comDocGo Announces Record Fourth Quarter and Full-Year 2023 ResultsFebruary 28, 2024 | finance.yahoo.comDocGo Inc (DCGO) Reports Record Q4 and Full-Year 2023 Results, Updates 2024 OutlookSee More Headlines Receive DCGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DocGo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/29/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:DCGO CUSIPN/A CIK1822359 Webwww.docgo.com Phone844-443-6246FaxN/AEmployees4,164Year FoundedN/APrice Target and Rating Average Stock Price Target$10.83 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+200.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E Ratio51.43 Forward P/E Ratio10.29 P/E Growth0.36Net Income$6.86 million Net Margins1.10% Pretax Margin2.61% Return on Equity2.01% Return on Assets1.37% Debt Debt-to-Equity RatioN/A Current Ratio1.99 Quick Ratio1.99 Sales & Book Value Annual Sales$624.29 million Price / Sales0.60 Cash Flow$0.21 per share Price / Cash Flow16.96 Book Value$2.93 per share Price / Book1.23Miscellaneous Outstanding Shares104,170,000Free Float89,816,000Market Cap$375.01 million OptionableOptionable Beta0.91 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Lee Bienstock (Age 39)CEO & Director Comp: $1.24MMr. Ely D. Tendler (Age 56)General Counsel, Secretary & Director Mr. Norman Rosenberg (Age 54)Treasurer & CFO Mike ColeVice President of Investor RelationsMr. Stephen Sugrue (Age 52)Chief Compliance Officer Mr. Ben ShermanEVP of Corporate DevelopmentMs. Rosemarie MilanoVice President of Human ResourcesMr. Andre Oberholzer CPA (Age 66)Executive Vice President of Strategy Comp: $1.75MMr. Aaron SeversChief Product OfficerMs. Vrenely MunozChief Revenue OfficerMore ExecutivesKey CompetitorsGeneDxNASDAQ:WGSSharecareNASDAQ:SHCRQuantum-SiNASDAQ:QSITalkspaceNASDAQ:TALKInnovAgeNASDAQ:INNVView All CompetitorsInsiders & InstitutionsVerdence Capital Advisors LLCBought 15,881 shares on 4/26/2024Ownership: 0.015%WCM Investment Management LLCBought 44,359 shares on 4/25/2024Ownership: 2.522%Simplex Trading LLCBought 7,500 shares on 4/25/2024Ownership: 0.000%Pasadena Private Wealth LLCBought 310,180 shares on 4/16/2024Ownership: 0.380%Michael J BurdiekBought 10,000 shares on 3/14/2024Total: $36,100.00 ($3.61/share)View All Insider TransactionsView All Institutional Transactions DCGO Stock Analysis - Frequently Asked Questions Should I buy or sell DocGo stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DocGo in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DCGO shares. View DCGO analyst ratings or view top-rated stocks. What is DocGo's stock price target for 2024? 5 brokers have issued 12 month price objectives for DocGo's stock. Their DCGO share price targets range from $8.00 to $16.00. On average, they anticipate the company's share price to reach $10.83 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price. View analysts price targets for DCGO or view top-rated stocks among Wall Street analysts. How have DCGO shares performed in 2024? DocGo's stock was trading at $5.59 on January 1st, 2024. Since then, DCGO stock has decreased by 35.2% and is now trading at $3.62. View the best growth stocks for 2024 here. Are investors shorting DocGo? DocGo saw a drop in short interest in April. As of April 15th, there was short interest totaling 9,260,000 shares, a drop of 11.7% from the March 31st total of 10,490,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is presently 8.7 days. Currently, 10.7% of the company's stock are short sold. View DocGo's Short Interest. When is DocGo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our DCGO earnings forecast. How can I listen to DocGo's earnings call? DocGo will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were DocGo's earnings last quarter? DocGo Inc. (NASDAQ:DCGO) released its earnings results on Wednesday, February, 28th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.07. The company had revenue of $199.25 million for the quarter, compared to the consensus estimate of $195.48 million. DocGo had a trailing twelve-month return on equity of 2.01% and a net margin of 1.10%. What ETF holds DocGo's stock? Global X Telemedicine & Digital Health ETF holds 97,844 shares of DCGO stock, representing 0.70% of its portfolio. What guidance has DocGo issued on next quarter's earnings? DocGo updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $720.0 million-$750.0 million, compared to the consensus revenue estimate of $753.9 million. Who are DocGo's major shareholders? DocGo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (2.52%), Pasadena Private Wealth LLC (0.38%), Verdence Capital Advisors LLC (0.02%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adriaan Stephanus Oberholzer, Anthony Capone, Ely D Tendler, James M Travers, Lee Bienstock, Michael J Burdiek and Stephen Sugrue. View institutional ownership trends. How do I buy shares of DocGo? Shares of DCGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCGO) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DocGo Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
